SOAT1 and Opportunistic infection: Using ruxolitinib, a direct block of the SARS-CoV-2 enters the cell has been noticed. Although there is a risk of adverse effects (opportunistic infections to the immunosuppression must also be considered), it significantly impacts overcoming complications due to immune hyperactivation by the JAK/STAT signaling pathway.